Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics shares rise as it gains major customer for complete heart analysis system

The University of Ottawa Heart Institute, Canada’s largest heart health centre, will use Ventripoint’s system to assess cardiac patients
doctor holding heart
The Toronto-based health care company’s system uses artificial intelligence to streamline volumetric measurements and ejection fractions for all four heart chambers

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) gained a major new customer for its VMS+ complete heart analysis system on Monday.

The University of Ottawa Heart Institute, the largest heart health centre in Canada, ordered Ventripoint’s system to use in clinical assessment of cardiac patients.

The new system will be used for research into valvular heart disease, infective endocarditis and aortic diseases, with a specific focus on the application of ultrasound in the study of cardiac structure and function, the company said in a statement.

Shares of Ventripoint jumped nearly 6% Monday to C$0.18 in Toronto, and traded at US$0.13 in the US.

READ: Ventripoint showcases its latest VMS+3.0 cardio-monitoring system at American College of Cardiology's 68th Annual conference

The Toronto-based health care company’s system uses artificial intelligence to streamline volumetric measurements and ejection fractions for all four heart chambers from standard two-dimensional images.

The results are equivalent to those from standard MRI testing, the only approved method currently on the market.

Initial research will test the hypothesis that right ventricular volume determined by Ventripoint’s system can be used as a more reliable and quantitative method to assess patients with tricuspid regurgitation.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use